The New England Journal of Medicine (NEJM) RSS feed -- Search Results in Hematology/Oncology. NEJM (https://www.nejm.org) is a weekly general medical journal that publishes new medical research findings, review articles, and editorial opinion on a wide variety of topics of importance to biomedical science and clinical practice. https://www.nejm.org/action/showPodcastsFeeds NEJM Group Thu, 23 Apr 2026 12:25:43 GMT 2026 NEJM Group en-us 1440 Among men with locally advanced prostate cancer, transdermal estradiol was noninferior to LHRH agonists for 3-year metastasis-free survival and led to a lower incidence of hot flashes but a higher incidence of gynecomastia. https://www.nejm.org/doi/full/10.1056/NEJMoa2511781?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2511781 Ruth E. Langley, Duncan C. Gilbert, Stephen Mangar, Stuart Rosen, Ellie Bourmaki, Hannah L. Rush, Subramaniam Kananga Sundaram, Abdulla Alhasso, Roger Kockelbergh, Hoda Abdel-Aty, Claire L. Amos, Louise Brown, Simon Brown, Charlene Carvalho, Kitty Chan, Gerald Collins, William Cross, John Deighan, Sanjay Dixit, Trinh Duong, James Dyer, Joanna Gale, Silke Gillessen, Anna Griffiths, Marc Laniado, Anna Lydon, Neil McPhail, Archie MacNair, Sanjeev Madaan, John Marshall, David Matheson, Robin Millman, Wael Mohamed, Laura Murphy, Krishna Narahari, Christopher Parker, Miguel Panades, Alvan Pope, Arpita Raval, Angus Robinson, Martin Russell, Christopher Scrase, Matthew Sydes, Rafal Turo, Ram Venkitaraman, Simona Wade, Howard Kynaston, Gerhardt Attard, Nicholas D. James, Noel Clarke, Mahesh K. Parmar, Matthew Nankivell, the STAMPEDE-1 and PATCH Investigators† 2026-04-23 Transdermal Estradiol Patches in Locally Advanced Prostate Cancer In a placebo-controlled trial involving patients with noncardioembolic ischemic stroke or high-risk TIA, asundexian added to antiplatelet therapy led to a lower risk of ischemic stroke without increasing major bleeding. https://www.nejm.org/doi/full/10.1056/NEJMoa2513880?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2513880 Mukul Sharma, Qiang Dong, Teruyuki Hirano, Scott E. Kasner, Jeffrey L. Saver, Jaime Masjuan, Andrew M. Demchuk, Charlotte Cordonnier, Daniel Bereczki, Georgios Tsivgoulis, Roland Veltkamp, Ivan Staikov, Hee-Joon Bae, Bruce C.V. Campbell, Andrea Zini, I-Hui Lee, Martin Kovar, Robert Mikulik, Robin Lemmens, José M. Ferro, Thompson Robinson, Hanne Christensen, Serefnur Ozturk, Ronen R. Leker, Peter Turcani, Agnieszka Slowik, Pablo Amaya, Fan Kee Hoo, Gian Marco De Marchis, Michael Knoflach, P.N. Sylaja, Jukka Putaala, Jonathan M. Coutinho, H. Bart van der Worp, Evija Miglane, Vaidas Matijošaitis, Arne G. Lindgren, Gisele Sampaio Silva, Else Charlotte Sandset, Saule T. Turuspekova, Pierre Amarenco, Kevin N. Sheth, Eric E. Smith, John W. Eikelboom, Raed A. Joundi, Karleen Schulze, Lizhen Xu, Laura Heenan, Pablo Colorado, Lars Keller, Eva Muehlhofer, Christoph Neumann, Hardi Mundl, Ashkan Shoamanesh, the OCEANIC-STROKE Investigators* 2026-04-16 Asundexian for Secondary Stroke Prevention In a phase 3 trial, ianalumab plus eltrombopag led to a longer time to treatment failure than placebo plus eltrombopag, with a stable platelet response at 6 months in a higher percentage of patients with 9 mg/kg of ianalumab than with placebo. https://www.nejm.org/doi/full/10.1056/NEJMoa2515168?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2515168 Adam Cuker, Thomas Stauch, Nichola Cooper, Hanny Al-Samkari, Marc Michel, Waleed Ghanima, Patrick Urban, Justyna Fronczek, Matthew Foster, Marine Weill, Lei Zhang, Ming Hou, Thomas Zander, Azizan Sharif, Jing Sun, Uttam Kumar Nath, Roger Schutgens, Elena Rossi, Lien Deleu, Libor Červinek, Jae-Ho Yoon, Hung Chang, Theera Ruchutrakool, Masaki Iino, Tatsunori Goto, Francesco Zaja, the VAYHIT2 Investigators* 2026-04-16 Ianalumab plus Eltrombopag in Immune Thrombocytopenia Combined oral contraceptives and hormone-replacement therapy increase the risk of venous thromboembolism, although the absolute risk is low. Transdermal estradiol and micronized progesterone carry lower risk. https://www.nejm.org/doi/full/10.1056/NEJMra2202438?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMra2202438 Leslie Skeith, Shannon M. Bates 2026-04-16 Sex Hormone Influences on Venous Thrombotic and Cardiovascular Risk Despite the implementation of efficacious interventions for secondary prevention, patients with ischemic stroke or transient ischemic attack (TIA) remain at substantial residual risk for short- and long-term recurrent ischemic stroke and coronary events.1,2 Approximately three quarters of ischemic strokes or TIAs are noncardioembolic and may be attributable to... https://www.nejm.org/doi/full/10.1056/NEJMe2601859?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2601859 Marion Boulanger 2026-04-16 Asundexian for Noncardioembolic Ischemic Stroke The Trump administration’s wide-ranging actions to dismantle U.S. environmental regulations will cause long-lasting health harms, disproportionately affecting low-income and other vulnerable groups. https://www.nejm.org/doi/full/10.1056/NEJMp2514370?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMp2514370 Adam W. Gaffney, David Himmelstein, Steffie Woolhandler, Sancia Sehdev, Philip J. Landrigan 2026-04-16 The Dismantling of Environmental Protections — A Grave Threat to America’s Health In a patient with metastatic cervical cancer treated with the nectin-4–targeted antibody–drug conjugate bulumtatug fuvedotin, a new hepatic lesion proved to be pseudoprogression and resolved with continued therapy. https://www.nejm.org/doi/full/10.1056/NEJMc2518316?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMc2518316 Shanbing Wang, Jiapei Liu, Fang Xie 2026-04-16 Hepatic Pseudoprogression after Treatment with Nectin-4–Targeted Antibody–Drug Conjugate In a phase 1 trial of first-line zongertinib for HER2-mutated non–small-cell lung cancer, an objective response occurred in 76% of patients, with a median progression-free survival of 14.4 months. https://www.nejm.org/doi/full/10.1056/NEJMoa2516969?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2516969 John V. Heymach, Noboru Yamamoto, Nicolas Girard, Gerrina Ruiter, Egbert F. Smit, David Planchard, Ernest Nadal, Yi-Long Wu, Jon Zugazagoitia, Hai-Yan Tu, Christina S. Baik, Kiyotaka Yoh, Ross A. Soo, Yanqiu Zhao, Joshua K. Sabari, Martin Wermke, Matthias Scheffler, Myung-Ju Ahn, Kristie Fernamberg, Lukas Schroeter, Behbood Sadrolhefazi, Claus Thamer, Sabina Eigenbrod-Giese, Sanjay Popat, the Beamion LUNG-1 Investigators* 2026-04-15 First-Line Zongertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer The discovery that many lung cancers are driven by a single dominant constitutively activated “driver” oncogene represented a quantum leap in the therapy of lung cancer. Potent small molecules were developed that could turn off these genes, with dramatic clinical therapeutic efficacy. Before their discovery, cancer therapeutics were identified by... https://www.nejm.org/doi/full/10.1056/NEJMe2603357?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2603357 David P. Carbone 2026-04-15 EGFR’s Poor Sibling Post-thrombotic syndrome is the most common chronic complication of deep-vein thrombosis (DVT), affecting 20 to 50% of patients with DVT and causing debilitating symptoms involving the limbs — including pain, swelling, skin changes, and venous ulcers — that substantially reduce quality of life and impose considerable socioeconomic burden.1 ... https://www.nejm.org/doi/full/10.1056/NEJMe2603048?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2603048 Ronald Luiz Gomes Flumignan, Luís Carlos Uta Nakano 2026-04-13 Stenting for Post-Thrombotic Syndrome — A Step Forward Among adults with persistent or chronic ITP, the incidence of adverse events with mezagitamab appeared to be similar to that with placebo. Mezagitamab treatment appeared to result in increased platelet counts at all three doses tested. https://www.nejm.org/doi/full/10.1056/NEJMoa2513120?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2513120 David J. Kuter, Katsuhiro Miura, Andrea Patriarca, Dražen Pulanić, Atanas Radinoff, Katya Sapunarova, Antonia Syrigou, Renchi Yang, Van Anh Nguyen, Emily Skelton, Scarlett Wang, Donald L. Yee, Parth Patwari, the Mezagitamab ITP Phase 2 Trial Investigators* 2026-04-09 A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia In a phase 1 trial of setidegrasib, a KRAS G12D degrader, 42% of patients had adverse events of grade 3 or higher; 36% of patients with NSCLC and 24% of those with pancreatic cancer had a response. https://www.nejm.org/doi/full/10.1056/NEJMoa2600752?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2600752 Wungki Park, Anup Kasi, Alexander I. Spira, Luis Paz-Ares Rodríguez, Benjamin O. Herzberg, Meredith S. Pelster, Anthony W. Tolcher, Yasutoshi Kuboki, Shigehisa Kitano, Hirokazu Shoji, Judy S. Wang, Jordan D. Berlin, Antoine Hollebecque, Patricia LoRusso, Christos Fountzilas, Philippe A. Cassier, Tomohiro Nishina, Daisuke Sakai, Chiaki Inagaki, Daniel Morgensztern, Makoto Ueno, Minkyu Jung, Sang-We Kim, Pasi A. Jänne, Antoine Italiano, Benoît You, T Macarulla, Hisaki Fujii, Aditya Shetty, Ying Lu, Daniel Cui, Shilpa Kadam, Stanley C. Gill, Junko Toyoshima, Takeshi Saito, Jonathan W. Goldman 2026-04-09 Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer A study in a mouse model of MYCN-amplified neuroblastoma implicates polyamine levels in affecting the makeup of the proteome and biologic characteristics of the tumor. https://www.nejm.org/doi/full/10.1056/NEJMcibr2516825?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcibr2516825 Michelle Haber, Murray D. Norris 2026-04-09 Altering the Diet to Rewire Cancer An 83-year-old woman with worsening type 2 diabetes presented with a 6-month history of painful rash. Hyperpigmented plaques with coalescing erosions and blisters were seen. Abdominal CT revealed a mass in the tail of the pancreas. https://www.nejm.org/doi/full/10.1056/NEJMicm2516331?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMicm2516331 Jia-An Hung, Ming-Chieh Lin 2026-04-09 Necrolytic Migratory Erythema In this study, a Cas12a–guide RNA complex was used to target the promoters of HBG1 and HBG2 in autologous stem cells to treat sickle cell disease. https://www.nejm.org/doi/full/10.1056/NEJMoa2415550?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2415550 Rabi Hanna, Haydar Frangoul, Luis Pineiro, Christopher McKinney, Markus Mapara, Jignesh Dalal, Hemalatha G. Rangarajan, Harold Atkins, Akshay Sharma, Kai-Hsin Chang, Michael C. Jaskolka, Keunpyo Kim, Qifeng Yu, Baisong Mei, Olubunmi Afonja, Mark C. Walters, the RUBY Investigators* 2026-04-02 CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease In cisplatin-ineligible patients with muscle-invasive bladder cancer, enfortumab vedotin–pembrolizumab plus surgery led to better event-free survival (74.7%, vs. 39.4%) and overall survival (79.7%, vs. 63.1%) than surgery alone at 2 years. https://www.nejm.org/doi/full/10.1056/NEJMoa2511674?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2511674 Christof Vulsteke, Nabil Adra, Pongwut Danchaivijitr, Maksym Sabadash, Alejo Rodriguez-Vida, Zhentao Zhang, Vagif Atduev, Y. Emre Göger, Steffen Rausch, Seok-Ho Kang, Yohann Loriot, Jens Bedke, Matthew D. Galsky, Peter H. O’Donnell, Gunhild von Amsberg, Nimira Alimohamed, Grzegorz Sulimka, Shilpa Gupta, Viktor Paramonov, Keita Nakane, Michael Mihm, Changting Meng, Caizhi David Huang, Chethan Ramamurthy, Blanca Homet Moreno, Anders Ullén, the KEYNOTE-905/EV-303 Investigators* 2026-04-02 Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer In this study, a Cas12a–guide RNA complex was used to target the promoters of HBG1 and HBG2 in autologous stem cells to treat transfusion-dependent β-thalassemia. https://www.nejm.org/doi/full/10.1056/NEJMoa2501277?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2501277 Haydar Frangoul, Rabi Hanna, Mark C. Walters, Roy L. Kao, Clinton Carroll, Meghann McManus, Kai-Hsin Chang, Michael C. Jaskolka, Keunpyo Kim, Qifeng Yu, Nnenna Badamosi, Baisong Mei, Olubunmi Afonja, Alexis Thompson, the EdiThal Investigators* 2026-04-02 CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia Transfusion-dependent β-thalassemia and sickle cell disease, both characterized by defective hemoglobin synthesis, are the most common monogenic diseases worldwide. Each year, approximately 60,000 infants are born with transfusion-dependent β-thalassemia, and 500,000 infants receive a diagnosis of sickle cell disease.1,2 Historically, patients with these disorders have rarely survived beyond... https://www.nejm.org/doi/full/10.1056/NEJMe2602194?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2602194 Franco Locatelli 2026-04-02 More Options for Gene Editing in Hemoglobinopathies Although bladder preservation with trimodal therapy is a category 1 recommendation in the National Comprehensive Cancer Network (NCCN) guidelines for appropriately selected patients with muscle-invasive bladder cancer, the real-world adoption of this type of therapy in the United States remains disappointingly low. Contemporary data suggest that only half the patients... https://www.nejm.org/doi/full/10.1056/NEJMe2515777?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2515777 Parminder Singh, Seth P. Lerner 2026-04-02 Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy In this study involving persons with sickle cell disease, adenine base editing was used to target the promoters of HBG1 and HBG2 in autologous hematopoietic stem cells to increase fetal hemoglobin expression. https://www.nejm.org/doi/full/10.1056/NEJMoa2504835?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2504835 Ashish O. Gupta, Akshay Sharma, Haydar Frangoul, Julie Kanter, Markus Y. Mapara, Jignesh Dalal, Asif Alavi, Jennifer J. Jaroscak, Ernesto Ayala, John F. DiPersio, Edward D. Ziga, Mary Eapen, Stacey Rifkin-Zenenberg, Alex C. Minella, Yinzhong Chen, Sarah Chesler, Srikanth Ambati, Thomas S. Bowman, Bahru Habtemariam, Marcelyne Joseney-Antoine, Priya S. Chockalingam, Ling Lin, Sunita Goyal, Amy Simon, Alexis A. Thompson, Matthew M. Heeney, the BEACON Investigators* 2026-04-01 Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease